Abbvie Inc

NYSE:ABBV  
107.75
-0.33 (-0.30%)
4:35:10 PM EDT: $107.50 -0.25 (-0.23%)
Products, Strategic Combinations

Abbvie And Regenxbio Announce Eye Care Collaboration

Published: 09/13/2021 11:55 GMT
Abbvie Inc (ABBV) - Abbvie and Regenxbio Announce Eye Care Collaboration.
Abbvie Inc - Abbvie Will Pay Regenxbio a $370 Million Upfront Payment.
Abbvie Inc - Deal Includes Potential for Regenxbio to Receive Up to $1.38 Billion in Additional Development, Regulatory and Commercial Milestones.
Abbvie Inc - Deal for Regenxbio and Abbvie Will Share Equally in Profits From Net Sales of Rgx-314 in U.S.abbvie Inc - Deal for Abbvie Will Pay Regenxbio Tiered Royalties on Net Sales of Rgx-314 Outside U.S.abbvie Inc - Abbvie Will Pay Regenxbio Tiered Royalties on Net Sales of Rgx-314 Outside U.S.abbvie Inc - Regenxbio Will Lead Manufacturing of Rgx-314 for Clinical Development and U.S. Commercial Supply.
Abbvie Inc - Abbvie Will Lead Manufacturing of Rgx-314 for Commercial Supply Outside U.S.abbvie Inc - Regenxbio Will Be Responsible for Completion of Ongoing Trials of Rgx-314.
Abbvie Inc - Abbvie Will Lead Clinical Development and Commercialization of Rgx-314 Globally.
Abbvie Inc - Abbvie and Regenxbio Will Collaborate and Share Costs on Additional Trials of Rgx-314.